<?xml version="1.0" encoding="UTF-8"?>
<p id="p0005">Coronavirus disease 2019 (COVID-19), caused by the RNA virus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has rapidly spread worldwide since its discovery in December 2019. (
 <xref rid="bb0060" ref-type="bibr">Zhu et al., 2020</xref>) The World Health Organization (WHO) declared COVID-19 a pandemic in March 2020, and currently there are over 6 million cases and greater than 350,000 deaths globally. (
 <xref rid="bb0050" ref-type="bibr">World Health Organization, 2020</xref>) Early in the pandemic, our facility established a collection program for the experimental COVID-19 intravenous therapy known as COVID-19 Convalescent Plasma (CCP), which is derived from individuals who have recovered from COVID-19. Plasma antibodies from a recovered COVID-19 patient might shorten illness duration, reduce morbidity, and potentially prevent death when administered to a COVID-19 patient with active infection. (
 <xref rid="bb0015" ref-type="bibr">Duan et al., 2020</xref>) In addition, convalescent plasma has been used in previous viral epidemics such as those caused by SARS-CoV-1, Ebola, and Influenza A virus type H1N1. (
 <xref rid="bb0010" ref-type="bibr">Cheng et al., 2005</xref>; 
 <xref rid="bb0055" ref-type="bibr">Zhou et al., 2007</xref>; 
 <xref rid="bb0045" ref-type="bibr">World Health Organization, 2014</xref>; 
 <xref rid="bb0020" ref-type="bibr">Hung et al., 2011</xref>)
</p>
